Outcomes of 19 unplanned pregnancies in women participating in phase 2 or 3 eliglustat clinical trials and 18 pregnancies in the partners of men who participated in these trials

被引：2
|
作者：
Balwani, Manisha [1 ]
Lukina, Elena [2 ]
Belmatoug, Nadia [3 ]
Watman, Nora [4 ]
Hughes, Derralynn [5 ]
Gaemers, Sebastiaan J. M. [6 ]
Kim, Yestle [6 ]
Foster, Mererdith [6 ]
Peterschmitt, M. Judith [6 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Natl Res Ctr Hematol, Moscow, Russia
[3] Univ Hosp Paris Nord Val de Seine, Paris, France
[4] Hosp Ramos Mejia, Buenos Aires, DF, Argentina
[5] UCL, Royal Free London NHS Fdn Trust, London, England
[6] Sanofi Genzyme, Cambridge, MA USA
来源：
MOLECULAR GENETICS AND METABOLISM | 2019年 / 126卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2018.12.047
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
31
引用
收藏
页码：S27 / S28
页数：2
相关论文
共 32 条
  • [21] ONSET OF ACTION AND TIME TO EFFICACY OF AVANAFIL, A NOVEL, RAPID-ONSET PDE5 INHIBITOR IN MEN WITH MILD TO SEVERE ERECTILE DYSFUNCTION: DATA FROM PHASE 2 AND PHASE 3 CLINICAL TRIALS
    Hellstrom, Wayne J. G.
    Freier, Matthew T.
    Serefoglu, Ege Can
    Lewis, Ronald W.
    Peterson, Craig A.
    DiDonato, Karen
    Day, Wesley W.
    JOURNAL OF UROLOGY, 2012, 187 (04): : E600 - E600
  • [22] Deucravacitinib in moderate to severe plaque psoriasis: Correlations between patient-reported outcomes and clinical responses in the phase 3 clinical trials POETYK PSO-1 and POETYK PSO-2
    Rubel, Diana
    Armstrong, April W.
    Papp, Kim
    Zhuo, Joe
    Becker, Brandon
    Zhong, Yichen
    Beaumont, Jennifer
    DeRosa, Michael
    Kisa, Renata M.
    Banerjee, Subhashis
    Strober, Bruce
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2023, 64 : 71 - 72
  • [23] EARLY PATIENT-REPORTED OUTCOMES AND CLINICAL OUTCOMES WITH ABT-494 IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS WHO ARE INADEQUATE RESPONDERS TO METHOTREXATE OR TUMOR NECROSIS FACTOR INHIBITORS: POST-HOC ANALYSIS OF PHASE 2 RANDOMIZED CONTROLLED TRIALS
    Strand, V.
    Tundia, N.
    Song, I. H.
    Meerwein, S.
    Lin, J.
    Chen, N.
    Friedman, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 855 - 855
  • [24] Patient-reported outcomes among adults living with HIV-1 who were randomly allocated to B/F/TAF versus DTG/ABC/3TC in two Phase 3 controlled clinical trials over 48 weeks
    Wohl, D.
    Clarke, A.
    Maggiolo, F.
    Garner, W.
    Martin, H.
    HIV MEDICINE, 2019, 20 : 63 - 63
  • [25] Association Between Achievement of Clinical Disease Control and Improvement in Patient-Reported Outcomes and Quality of Life in Patients With Psoriatic Arthritis in the Phase 3 SELECT-PsA 1 and 2 Randomized Controlled Trials
    Kavanaugh, Arthur
    Mease, Philip
    Gossec, Laure
    Ranza, Roberto
    Tsuji, Shigeyoshi
    Douglas, Kevin
    Lane, Michael
    Lippe, Ralph
    Mittal, Manish
    Gao, Tianming
    Setty, Arathi
    Ciecinski, Sandra
    Aletaha, Daniel
    Nash, Peter
    ACR OPEN RHEUMATOLOGY, 2024, 6 (11) : 736 - 745
  • [26] LINZAGOLIX MAY ADDRESS THE LONG-TERM TREATMENT NEEDS OF WOMEN WITH UTERINE FIBROIDS (UF) WHO HAVE CONTRAINDICATIONS TO HORMONAL ADD-BACK THERAPY (ABT): RESULTS FROM TWO PHASE 3 RANDOMIZED CLINICAL TRIALS.
    Bradley, Linda D.
    Marsh, Erica E.
    Garner, Elizabeth
    FERTILITY AND STERILITY, 2020, 114 (03) : E522 - E522
  • [27] Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3) (vol 18, pg 273, 2017)
    Blauvelt, Andrew
    Papp, Kim A.
    Griffiths, Christopher E. M.
    Puig, Luis
    Weisman, Jamie
    Dutronc, Yves
    Kerr, Lisa Farmer
    Ilo, Dapo
    Mallbris, Lotus
    Augustin, Matthias
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2018, 19 (03) : 457 - 457
  • [28] SC peginterferon beta-1a every 2 weeks demonstrated better clinical outcomes than SC interferon beta-1a TIW in patients with RMS, using a matching-adjusted comparison of 5 Phase 3 trials
    Coyle, Patricia
    Shang, Shulian
    Castrillo-Viguera, Carmen
    NEUROLOGY, 2017, 88
  • [29] SC peginterferon beta-1a every 2 weeks demonstrated better clinical outcomes than SC interferon beta-1a TIW in patients with RMS, using a matching-adjusted comparison of 7 Phase 3 trials
    Coyle, P.
    Shang, S.
    You, X.
    Castrillo-Viguera, C.
    Fiore, D.
    Werneburg, B.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 776 - 776
  • [30] Peginterferon beta-1a every 2 weeks demonstrates better clinical outcomes than glatiramer acetate 40 mg/mL 3 times a week in patients with relapsing-remitting multiple sclerosis using a matching-adjusted indirect comparison of phase 3 trials
    Scott, T.
    Su, R.
    Naylor, M. L.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 864 - 865
1234